Table 1.
Clinical, epidemiological data and comparison regarding hair regrowth in the DPCP and anthralin groups.
| Variable | DPCP, n (%) | Anthralin, n (%) | p |
|---|---|---|---|
| Sex | 11F / 2M | 10F / 1M | >0.999 |
| Age, mean (DP) | 36.8 (10.7) | 34.1 (7.0) | 0.474 |
| Clinical type | |||
| Multifocal | 5 | 3 | 0.093 |
| TAA | 2 | 1 | 0.642 |
| UAA | 6 | 7 | 0.392 |
| Age at the 1st episode, mean (SD) | 23.7 (14.8) | 17.8 (11.3) | 0.293 |
| Episode duration in months | |||
| Median (IQR) | 36 (108) | 24 (102) | 0.675 |
| Minimum/Maximum | 8/192 | 8/240 | |
| Atopy | 4 (30.8) | 5 (45.5) | 0.675 |
| Ungual alterations | 3 (23.1) | 3 (27.3) | >0.999 |
| Anti-H1 use | 2 (15.4) | 1 (9.1) | >0.999 |
| Previous treatments | |||
| Oral corticoid | 8 (61.5) | 8 (72.7) | 0.562 |
| Corticoid infiltration | 6 (56.2) | 8 (72.7) | 0.240 |
| Topical corticoid | 7 (43.8) | 4 (36.4) | 0.444 |
| Minoxidil | 5 (38.5) | 7 (63.6) | 0.414 |
| IV Corticoid | 1 (7.7) | 0 (0.0) | >0.999 |
| Anthralin | 1 (7.7) | 2 (18.2) | 0.576 |
| DPCP | 2 (15.4) | 3 (27.3) | 0.630 |
| Methotrexate | 1 (7.7) | 3 (27.3) | 0.300 |
| Chloroquine | 0 (0.0) | 1 (9.1) | 0.458 |
| Results | |||
| Initial SALT score | |||
| Median (IQR) | 98 (28.5) | 10 (7.2) | 0.178 |
| Minimum / Maximum | 60.1 / 100 | 93.4 / 100 | |
| 6-month SALT score | |||
| Median (IQR) | 89.9 (29.0) | 99.9 (0.72) | 0.242 |
| Minimum / Maximum | 60.9 / 100 | 75.1 / 100 |
SDP, Standard Deviation; IQR, Interquartile Range; Anti-H1, Anti-Histaminic drugs; IV, Intravenous.